Harbor BioSciences, Inc. Receives Patent for Triolex(R) and Other Compounds

SAN DIEGO, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds. Current data indicates that Triolex is a first-in-class compound for the treatment of responsive insulin resistant pre-diabetes and type 2 diabetes patients, operating by limiting inflammation in responsive patient populations.